Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN
This research is looking into a new medicine called Berubicin, which is being tested for a serious type of cancer known as central nervous system (CNS) lymphoma. This cancer affects your brain and spinal cord. The main goal of this early-stage study is to understand if Berubicin is safe when given with other standard cancer treatments and to figure out the best dose to use in future studies. Researchers will also be checking if the treatment helps keep the cancer from growing, shrinks tumours, and improves how long people live. They'll also look at how the body handles the medicine. The study is open to adults over 18 who have CNS lymphoma.
At a glance
What is this study about?
This research is looking at a new medicine called Berubicin for people with a type of cancer called central nervous system (CNS) lymphoma. This is a serious condition where cancer starts in or spreads to the brain and spinal cord. Finding new and better ways to treat this cancer is very important.
This study is happening in two parts. In the first part, called Phase I, the main aim is to check if Berubicin is safe when given alongside other common cancer treatments. Researchers will also be looking to find the right amount, or dose, of Berubicin to give, which will be used in future studies. This is crucial because it helps ensure the medicine is both effective and as safe as possible.
In the second part, called Phase II, the researchers will continue to gather information about safety but will also focus more on how well Berubicin works. They will be looking at several things, including how long people live after treatment, whether the cancer stops growing or shrinks, and if it delays the cancer from getting worse. They will also collect information about how the medicine moves through and is processed by the body. This information helps us understand if Berubicin could be a helpful new treatment option for people with CNS lymphoma.
Key takeaways
- This study is testing a new medicine called Berubicin for brain and spinal cord cancer (CNS lymphoma).
- Its main goals are to check the medicine's safety and find the best dose.
- It also aims to see if Berubicin helps stop cancer growth and improves patient outcomes.
- The study is for adults aged 18 and over who have CNS lymphoma.
- Participation involves receiving treatment and having regular health checks.
- You can withdraw from the study at any time.
Who may be eligible?
To be part of this study, you must be at least 18 years old. Both men and women are welcome to take part. The study is specifically for people who have central nervous system (CNS) lymphomas, which is a type of cancer affecting the brain and spinal cord.
More detailed health checks will be done by the study doctors to make sure the treatment is suitable and safe for you. These checks will look at your overall health, any other medical conditions you might have, and your current cancer treatment history.
The study team will carefully review all your medical information to confirm if you meet all the necessary requirements to participate. This ensures that the study is as safe as possible for everyone involved and that the results are reliable.
- Are you 18 years old or older?
- Have you been diagnosed with central nervous system (CNS) lymphoma?
- Are you able to attend regular hospital or clinic appointments?
- Are you willing to receive a new medicine alongside standard treatments?
- Are you comfortable with blood tests and scans as part of your monitoring?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to join this study, you will receive the study medicine, Berubicin, along with other standard cancer treatments. You will have regular visits to the hospital or clinic for these treatments and check-ups. These visits will involve blood tests, scans, and other assessments to monitor your health, how your body is responding to the medicine, and if the cancer is changing.
Doses of Berubicin may be adjusted based on how you respond and how you feel. The doctors and nurses will explain the full schedule of treatments and visits. The exact duration of your participation will depend on your individual response to the treatment, but careful monitoring will continue throughout the study period and potentially for some time afterwards.
Potential risks and benefits
Locations (1)
- —Poland
Common questions
What is CNS lymphoma?
CNS lymphoma is a type of cancer that starts in or spreads to your brain and spinal cord, which are parts of your central nervous system.
What is Berubicin?
Berubicin is a new medicine being tested as a potential treatment for CNS lymphoma. It's designed to fight cancer cells.
What does 'Phase I and Phase II' mean?
These are stages of clinical trials. Phase I focuses on safety and finding the right dose, while Phase II continues to study safety and also looks at how well the medicine works.
Will I still get my regular cancer treatment?
Yes, in this study, Berubicin is expected to be given along with other standard cancer treatments you might already receive, or that your doctor recommends.
Can I leave the study if I change my mind?
Yes, you can choose to stop participating in the study at any time, for any reason, and it won't affect your ongoing medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.